BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...and drug-resistant infections.Ribo applies for Shanghai STAR listingThe Shanghai Stock Exchange accepted an application from Suzhou Ribo Life Science Co. Ltd....
...its R&D team and construct a biochemical laboratory for internal compound testing. BC Staff ImmunoChina Eccogene Aegicare (Shenzhen) Technology Inhibikase Aivita Biomedical Suzhou Ribo Risen...
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

...Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an...
...Ribo in China Partnership” ). Targets CASP2 - Caspase-2 GCGR - Glucagon receptor Hongjiang Li, Staff Writer Suzhou Ribo Life Science Co. Ltd. Glucagon...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...China for the anti-PD-1 mAb in 1H20. RNAi play Suzhou Ribo raises series C RNAi company Suzhou Ribo Life Science Co. Ltd....
...Inc. (NASDAQ:NVUS), which is developing specialty drugs for ear nose and throat disorders. Hongjiang Li, Staff Writer Suzhou Ribo Life Science Co. Ltd. Hummingbird...
BioCentury | Apr 19, 2019
Finance

Hope for China’s academic spinouts

...time” (see “China’s Dysfunctional Patent Flood” ). High profile Peking University professors founding companies include Suzhou Ribo Life Science Co. Ltd....
...Pharma Inc. Chinese Academy of Sciences EdiGene Inc. GlaxoSmithKline plc Hua Medicine Ltd. I-Mab Biopharma Innovative Cellular Therapeutics Co. Ltd. Peking University Pfizer Inc. Roche Suzhou Ribo Life Science Co. Ltd. Zai...
BioCentury | Sep 15, 2017
Company News

China Resources invests in Converd

...Earlier this year, China Resources participated in a series B round for antisense company Suzhou Ribo Life Science Co. Ltd....
BioCentury | Sep 13, 2017
Company News

China Resources invests in Converd

...Earlier this year, China Resources participated in a series B round for antisense company Suzhou Ribo Life Science Co. Ltd....
BioCentury | Apr 21, 2017
Company News

Ionis, Suzhou Ribo deal

...Ionis said it granted Suzhou Ribo Life Science commercialization rights in China to two antisense drug candidates...
...Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Suzhou Ribo Life Science Co. Ltd. , Kushan, China Business: Cancer, Endocrine/Metabolic Shannon Lehnbeuter Ionis Pharmaceuticals Inc. Suzhou Ribo Life Science Co. Ltd....
BioCentury | Apr 18, 2017
Company News

Ionis, Ribo in China partnership

...Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said it granted Suzhou Ribo Life Science Co. Ltd. (Kushan, China) Chinese commercialization rights to two antisense...
...Beijing, China); ZHYT Investment Management; Legend Capital; GGV Capital; and Pan-Lin Asset Management. Becky Simon Ionis Pharmaceuticals Inc. Suzhou Ribo Life Science Co. Ltd....
BioCentury | Nov 9, 2015
Clinical News

QPI-1007: Phase II/III started

...as 3 injections 2 months apart in about 352 patients. RiboQuark -- a JV between Suzhou Ribo...
BioCentury | Jul 21, 2014
Clinical News

QPI-1007: Phase IIa started

...60 patients with unilateral acute primary angle-closure glaucoma. RiboQuark - a JV between RNAi companies Suzhou Ribo...
Items per page:
1 - 10 of 14
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...and drug-resistant infections.Ribo applies for Shanghai STAR listingThe Shanghai Stock Exchange accepted an application from Suzhou Ribo Life Science Co. Ltd....
...its R&D team and construct a biochemical laboratory for internal compound testing. BC Staff ImmunoChina Eccogene Aegicare (Shenzhen) Technology Inhibikase Aivita Biomedical Suzhou Ribo Risen...
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

...Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an...
...Ribo in China Partnership” ). Targets CASP2 - Caspase-2 GCGR - Glucagon receptor Hongjiang Li, Staff Writer Suzhou Ribo Life Science Co. Ltd. Glucagon...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...China for the anti-PD-1 mAb in 1H20. RNAi play Suzhou Ribo raises series C RNAi company Suzhou Ribo Life Science Co. Ltd....
...Inc. (NASDAQ:NVUS), which is developing specialty drugs for ear nose and throat disorders. Hongjiang Li, Staff Writer Suzhou Ribo Life Science Co. Ltd. Hummingbird...
BioCentury | Apr 19, 2019
Finance

Hope for China’s academic spinouts

...time” (see “China’s Dysfunctional Patent Flood” ). High profile Peking University professors founding companies include Suzhou Ribo Life Science Co. Ltd....
...Pharma Inc. Chinese Academy of Sciences EdiGene Inc. GlaxoSmithKline plc Hua Medicine Ltd. I-Mab Biopharma Innovative Cellular Therapeutics Co. Ltd. Peking University Pfizer Inc. Roche Suzhou Ribo Life Science Co. Ltd. Zai...
BioCentury | Sep 15, 2017
Company News

China Resources invests in Converd

...Earlier this year, China Resources participated in a series B round for antisense company Suzhou Ribo Life Science Co. Ltd....
BioCentury | Sep 13, 2017
Company News

China Resources invests in Converd

...Earlier this year, China Resources participated in a series B round for antisense company Suzhou Ribo Life Science Co. Ltd....
BioCentury | Apr 21, 2017
Company News

Ionis, Suzhou Ribo deal

...Ionis said it granted Suzhou Ribo Life Science commercialization rights in China to two antisense drug candidates...
...Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Suzhou Ribo Life Science Co. Ltd. , Kushan, China Business: Cancer, Endocrine/Metabolic Shannon Lehnbeuter Ionis Pharmaceuticals Inc. Suzhou Ribo Life Science Co. Ltd....
BioCentury | Apr 18, 2017
Company News

Ionis, Ribo in China partnership

...Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said it granted Suzhou Ribo Life Science Co. Ltd. (Kushan, China) Chinese commercialization rights to two antisense...
...Beijing, China); ZHYT Investment Management; Legend Capital; GGV Capital; and Pan-Lin Asset Management. Becky Simon Ionis Pharmaceuticals Inc. Suzhou Ribo Life Science Co. Ltd....
BioCentury | Nov 9, 2015
Clinical News

QPI-1007: Phase II/III started

...as 3 injections 2 months apart in about 352 patients. RiboQuark -- a JV between Suzhou Ribo...
BioCentury | Jul 21, 2014
Clinical News

QPI-1007: Phase IIa started

...60 patients with unilateral acute primary angle-closure glaucoma. RiboQuark - a JV between RNAi companies Suzhou Ribo...
Items per page:
1 - 10 of 14